IGC Pharma Q2 FY26 net loss widens to $3 million; revenue falls to $265,000

PUBT · 2d ago
IGC Pharma Q2 FY26 net loss widens to $3 million; revenue falls to $265,000
  • IGC Pharma posted Q2 net loss attributable to common stockholders of $3 million, or $0.03 a share, widening from $1.6 million, or $0.02.
  • Revenue fell 19.21% to about $265,000, while R&D expense climbed 64.51% to about $1.4 million on continued CALMA investment.
  • Selling, general and administrative costs rose 16.67% to about $1.4 million; cash and cash equivalents totaled about $331,000 at quarter-end.
  • CALMA Phase 2 trial hit its 146-patient baseline randomization target, moving within six additional randomizations of expected enrollment closure.
  • CEO Ram Mukunda said the focus is on follow-up, data quality and readiness for topline analysis, with Phase 2 topline data expected in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608170830ACCESSWRNAPR_____1207902) on August 17, 2026, and is solely responsible for the information contained therein.